Treatment of chronic akinetic mutism with atomoxetine: subtraction analysis of brain f-18 fluorodeoxyglucose positron emission tomographic images before and after medication: a case report

Akinetic mutism is a rare, complex neuropathologic disorder. The pharmaceutical treatment of akinetic mutism typically includes dopaminergic agents, but the resulting therapeutic effects are often unsatisfactory, and it remains unclear whether late treatment using these medications is effective. We...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical neuropharmacology Ročník 33; číslo 4; s. 209
Hlavní autoři:	Kim, Yong Wook, Shin, Ji-Cheol, An, Young-Sil
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.07.2010
Témata:	Akinetic Mutism - diagnostic imaging Akinetic Mutism - drug therapy Akinetic Mutism - metabolism Aneurysm, Ruptured - complications Atomoxetine Hydrochloride Cognition - drug effects Fluorodeoxyglucose F18 - metabolism Frontal Lobe - diagnostic imaging Frontal Lobe - drug effects Frontal Lobe - metabolism Glucose - metabolism Humans Male Middle Aged Norepinephrine Plasma Membrane Transport Proteins - antagonists & inhibitors Occipital Lobe - diagnostic imaging Occipital Lobe - drug effects Occipital Lobe - metabolism Positron-Emission Tomography Propylamines - therapeutic use Subarachnoid Hemorrhage - etiology Subtraction Technique Time Factors
ISSN:	1537-162X, 1537-162X
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Akinetic mutism is a rare, complex neuropathologic disorder. The pharmaceutical treatment of akinetic mutism typically includes dopaminergic agents, but the resulting therapeutic effects are often unsatisfactory, and it remains unclear whether late treatment using these medications is effective. We present a case study of a 53-year-old male patient who developed akinetic mutism for a period of 7 months after a subarachnoid hemorrhage. The hemorrhage was caused by a ruptured aneurysm in the right anterior communicating artery, followed by a secondary infarction in the territory of the right anterior cerebral artery. Baseline brain F-18 fluorodeoxyglucose positron emission tomographic images revealed decreased glucose metabolism in both frontal lobes. Treatment with atomoxetine, a selective norepinephrine reuptake inhibitor, for a period of 8 weeks led to a clinically significant improvement in the patient's cognitive function and activities of daily living. A subtraction brain positron emission tomographic analysis after atomoxetine medication revealed increased cerebral glucose metabolism in both the premotor and visual association cortices. Thus, we suggest that atomoxetine can be a useful therapeutic option in the treatment of chronic akinetic mutism.
Bibliografie:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1537-162X 1537-162X
DOI:	10.1097/WNF.0b013e3181dca948